eFFECTOR Therapeutics Inc (EFTR) Shares Plummet Below 1-Year High

The stock of eFFECTOR Therapeutics Inc (NASDAQ: EFTR) has decreased by -77.91 when compared to last closing price of 16.47. Despite this, the company has experienced a -72.95% fall in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-02-05 that SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that Steve Worland, Ph.D., president, and chief executive officer of eFFECTOR, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14th at 10:40 am ET.

Is It Worth Investing in eFFECTOR Therapeutics Inc (NASDAQ: EFTR) Right Now?

EFTR has 36-month beta value of 0.49. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for EFTR is 3.02M, and currently, short sellers hold a 10.53% ratio of that float. The average trading volume of EFTR on April 04, 2024 was 161.71K shares.

EFTR’s Market Performance

The stock of eFFECTOR Therapeutics Inc (EFTR) has seen a -72.95% decrease in the past week, with a -76.63% drop in the past month, and a -72.91% fall in the past quarter. The volatility ratio for the week is 13.48%, and the volatility levels for the past 30 days are at 13.03% for EFTR. The simple moving average for the past 20 days is -72.46% for EFTR’s stock, with a -75.00% simple moving average for the past 200 days.

Analysts’ Opinion of EFTR

Many brokerage firms have already submitted their reports for EFTR stocks, with Stifel repeating the rating for EFTR by listing it as a “Hold.” The predicted price for EFTR in the upcoming period, according to Stifel is $6.20 based on the research report published on January 25, 2022 of the previous year 2022.

Stifel, on the other hand, stated in their research note that they expect to see EFTR reach a price target of $20. The rating they have provided for EFTR stocks is “Buy” according to the report published on November 09th, 2021.

Credit Suisse gave a rating of “Outperform” to EFTR, setting the target price at $20 in the report published on October 12th of the previous year.

EFTR Trading at -70.39% from the 50-Day Moving Average

After a stumble in the market that brought EFTR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.17% of loss for the given period.

Volatility was left at 13.03%, however, over the last 30 days, the volatility rate increased by 13.48%, as shares sank -77.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -63.11% lower at present.

During the last 5 trading sessions, EFTR fell by -71.59%, which changed the moving average for the period of 200-days by -83.51% in comparison to the 20-day moving average, which settled at $12.57. In addition, eFFECTOR Therapeutics Inc saw -68.86% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at EFTR starting from SR ONE CAPITAL MANAGEMENT, LLC, who sale 609,163 shares at the price of $0.61 back on Nov 27 ’23. After this action, SR ONE CAPITAL MANAGEMENT, LLC now owns 1,821,415 shares of eFFECTOR Therapeutics Inc, valued at $369,457 using the latest closing price.

Stock Fundamentals for EFTR

The total capital return value is set at 6.49. Equity return is now at value -946.56, with -144.33 for asset returns.

Based on eFFECTOR Therapeutics Inc (EFTR), the company’s capital structure generated 1.42 points at debt to capital in total, while cash flow to debt ratio is standing at -1.52. The debt to equity ratio resting at -3.36. The interest coverage ratio of the stock is -24.02.

Currently, EBITDA for the company is -33.73 million with net debt to EBITDA at -0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.77.

Conclusion

To put it simply, eFFECTOR Therapeutics Inc (EFTR) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts